Summary:
A randomized, double blind study to evaluate the efficacy of tralokinumab in adults with uncontrolled asthma.
Qualified Participants Must:
• Be 18-75 years of age
•
Be currently taking asthma medication
•
Have hadd at least one exacerbations (asthma attack) within the year
Qualified Participants May Receive:
Study related medical care and investigational medication at no cost. May be compensated for time and travel.